DOCSLIB.ORG

Precise Disease Classification Optimizes Bundled Payments Session #99, March 7, 2018 Stuart Goldberg MD and Andrew Pecora MD

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Precise Disease Classification Optimizes Bundled Payments Session #99, March 7, 2018 Stuart Goldberg MD and Andrew Pecora MD Precise Disease Classification Optimizes Bundled Payments Session #99, March 7, 2018 Stuart Goldberg MD and Andrew Pecora MD 1 Conflict of Interest Stuart L Goldberg MD Salary: Cota Inc. Ownership Interests: Cota Inc. Andrew L Pecora MD Salary: Hackensack Meridian Network Patents: Cota Inc. Ownership Interests: Cota Inc. 2 Agenda • Dr. Goldberg – Value Based Payments – Understanding Bundles (pros and pitfalls) – A better classification schema to organize data & detect variance • Dr. Pecora – Applying the schema to a large cancer practice – Building a cancer bundle program – Models of identifying variance – Early results from the program 3 Learning Objectives 1. Define the key features of the bundled payment reform model and the potential pitfalls 2. Recognize how a precise disease classification system can help health systems better understand their patient populations 3. Apply a precise disease classification system to identify and reduce care variances among similar patients treated within a bundled payment model 4. Create a data- focused team to track and better manage bundled payment programs 5. Show how data can be used to improve understanding of treatment patterns at scale 4 Suppose you were offered A bundled payment for all services relating to the care of your breast cancer patients for 1 year $100,000 Is it a good deal? What else do you need to know? 5 We all recognize the concept of precision medicine -give the right therapy to the right patient But what about precision payment? - match the payment to a more homogenous patient population If you don’t know much about your patients you cannot predict the therapy or the costs 6 Medicine is moving to Value Based Payment Models – a drive to reduce costs while maintaining quality. 7 CMS.gov website 25-01-2016 Bundled Payment Models • A single payment for all services related to a specific treatment or condition for a defined period of time • May span multiple providers in multiple settings. • Providers assume financial risk for the cost of services for a particular treatment or condition as well as costs associated with preventable complications. • Promotes decreased spending (unnecessary and necessary?) • Promotes coordination of care, finding of efficiencies • Requires data and tracking, especially regarding maintenance of quality • Must account for case mix – otherwise significant risks 8 If every patient/case was the same: the costs should be similar • – easy to figure a margin • -- easy to find areas to cut costs and increase return • -- easy to monitor when changes work or don’t work • -- easy to identify doctors or procedures that are outliers • -- easy to track outcomes (quality) •But medicine is often complex: • Bundles have moved furthest in repetitive homogenous diseases (joint replacements) but are hardest in variable diseases (cancer) 9 Would understanding our patient populations help us build better bundles? • The current ICD-10 billing codes are extremely broad • ICD-10 does not capture the specificity needed to understand complex diseases nor does it capture important co-morbidities that drive treatments and costs • Breast cancer ICD-10 is C50.x with the modifiers only capturing gender and location within the breast 10 The Grocery Uses “Barcodes” to Identify Items Accurately characterizes each item Allows tracking from “farm to table” Volumes and Inventory Quality (benchmarking) Price Links11 to other databases Cota Nodal Address (CNA): Precisely Classify for Precision Analytics 12 100 Number150 200 250 300 350 of400 Patients450 500 550 600 650 700 750 50 Pecora AL Pecora et al: J 0 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… data) (real N Clin Oncol Oncol 33, Clin 2015 (suppl; abstr e17699) 01.02.01.00… CNA “Barcodes” facilitate identification CNA identification facilitate “Barcodes” ≈ 01.02.01.00… 01.02.01.00… NJ throughout patients cancer breast 3,000 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… • • • • 01.02.01.00… Population science and Payer interest in most common types common most in interest Payer and science Population identification trial research/clinical for subtypes rare “tag” Can disequilibrium) (biologic utilized 200 approximately Only possible; cancer breast for CNA different 5000 Over 01.02.01.00… homogeneous of populations 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 13 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… 01.02.01.00… Breast Cancer Treatment Strategies by CNA: Identifying Variance • Some phenotypes are treated the same; • Others have great variance • Understanding the variance is key 14 Pecora AL et al: J Clin Oncol 33, 2015 (suppl; abstr e17699) 14 Understanding Variance is Key to Success in Participating in Value Based Payment Reform • Not all diseases are the same • Not all patients are the same • Not all doctors treat the same disease the same way • Not all doctors treat the same disease the same way each time • Not all etc. etc.…. • Understanding these differences and planning is essential to minimize variances achieve the Triple Aim (plus provider stability) 15 Complex Diseases can be part of Value Programs • At Hackensack Meridian Health we have participated in several Bundled Programs in Cancer. • The CMMI Oncology Care Model – 6-month episodes triggered by the initiation of chemotherapy. – paid traditional Medicare fee-for-service (FFS) payments. – payments are aggregated and retrospectively compared with episode- specific target prices. – If requisite quality thresholds are met, and aggregate payments fall below the target, OCM practices receive a performance-based payment (PBP). – HOWEVER minimal case mix adjustments are made (even stage of cancer) 16 CNA Guided Care Oncology Program • Hackensack Meridian Health has developed an innovative cancer bundled care program with 1 year total cost of care episodes • Pilot with Horizon Blue Cross Blue Shield of NJ in 2018 (based on pilots conducted over past two years) • Proposal approved by PTAC (CMMI) 9 to 1 – (awaiting review by Secretary of Health and Human Services) 17 Development of a precision payment VBP 18 Program Starts by Analyzing Past Performances • 1503 patients with breast cancer treated during the past 3 yrs. • Understand type of patients (oncologic case mix) • In Oncology Care Model all would be just a few ICD codes • But in our CNA based program each patient is classified based on 18 different prognostic elements (to accurately understand differences and allow analytics) 19 Distribution of “Clinically Identical” Breast Cancer Patients at Hackensack Meridian as Sorted by the CNA classification system 1503 distinct breast cancer patients 468 different CNA cohorts 33% of all patients were in the top 10 CNAs 20 Breast Cancer Treatment Bundles Designed by Our Physicians • BUNDLES – A broad treatment strategy for which a projected price will be paid – Designed based on critical disease elements that dictate therapy – Examples: • Adjuvant her2neu oncogene negative • Adjuvant her2neu oncogene positive • Adjuvant patient observation only • Metastatic her2neu oncogene negative • Metastatic her2neu oncogene positive • Metastatic immunotherapy • Metastatic patient observation only 21 • LANES – More specified treatments within a bundle strategy – Payment is at the Bundle NOT Lane level – Examples in Bundle 1 (adjuvant her2neu oncogene negative) • Hormone only • Non-anthracycline based chemotherapy • Non-anthracycline based chemotherapy with radiotherapy • Anthracycline based chemotherapy • Anthracycline based chemotherapy with radiotherapy • Only radiotherapy 22 • SUBLANES – Drug level specificity of treatment – Examples (in Bundle 1, lane 1 – adjuvant, her2neu negative, hormone only) • Tamoxifen • Anastrazole • Letrozole • Anastrazole with leuprolide • Anastrazole with goserelin • Etc. 23 24 25 26 . 27 28 29 30 31 32 33 34 35 36 Applying this Precision Classification to our Bundled Program • Variation in treatment was observed by CNA. • Patterns differing by physicians more easily identified (example: echo vs MUGA saving hundreds per case) • The median reimbursement was $122,000 (which is all ICD-10 would provide). • By splitting the population into CNA cohorts, median reimbursement for the top 10 subgroups ranged from $27,500 (early stage, postmenopausal, hormone positive, her2neu negative, etc.) to $153,000 (metastatic, postmenopausal, hormone positive, etc.). Allows more tailored discussion of bundle prices 37 Using the precise classification of each patient’s cancer: • Able to understand the types of patients seen at our cancer center • Identify costs for the different types • Identify where the variances are occurring • Quickly assess outcomes and toxicities • Build a bundled program where the provider understands the average costs, and where savings can be made • Promote a collaboration between physicians based on data to improve care and reduce costs 38 Thank you -- Questions For more information: [email protected] [email protected] Also please complete the online session evaluation 39.
Load more

Recommended publications
  • Educational Objectives Target Audience Abstract Instructions Services for the Disabled Language/Translation Cme Accreditation Cr
    TARGET AUDIENCE PROGRAM REGISTRATION This conference is designed for medical, surgical and radiation Tuition: US$350 Physicians in Practice (prior to June 21, 2004) oncologists, as well as obstetricians, gynecologists and other US$400 Physicians (On/After June 21, 2004 & On-Site) physicians interested in leading edge information on breast US$200 Residents, Fellows, Nurses and Allied Health cancer care and the most promising clinical trials for their breast Professionals cancer or high risk patients. US$130 Accompanying Person to Dinner Reception Tuition is complimentary for Patient Advocates / Cancer Survivors EDUCATIONAL OBJECTIVES Tuition includes, admission to scientific sessions, a course syllabus, continental breakfast, refreshment breaks, a cocktail reception on Upon completion of this conference, participants should be able Thursday, July 22nd, and a dinner event on Friday, July 23rd, to: 2004. Understand the basic mechanisms of the development of breast cancer, its natural history, risk factors, genetic There will be an additional $150 fee for each of the three Surgical component and prognostic indicators; Hands-On Sessions and $100 for the Nursing Seminar. It is required that attendees register for the entire conference in order to register Be up-to-date on today’s diagnostic and treatment for the surgical sessions and/or the luncheons. controversial areas of invasive and non-invasive breast cancer Refunds will be made only if written notice of cancellation is received care; prior to May 21, 2004. A $75 fee is charged for all refunds. After Guide patients to the ongoing clinical trials and develop May 21, 2004, no refunds will be made. In cases where a course novel treatment concepts for future clinical trials; is cancelled due to insufficient registrations, a full tuition refund is made.
    [Show full text]
  • Research Day
    th 12Annual Department of Medicine Research Day Thursday, May 15, 2014 12:00 PM – 3:00 PM New Jersey Medical School Medical Science Building B Level, Room 610 & B Level, Grand Foyer Oral Presentations 4. Localized Facial Cold Urticaria: A Case Presentation and Literature Review Reenal Patel, MD; Alan Wolff, MD 12:00 noon to 1:30 p.m. MSB-B610 5. Hepatitis C Treated with an Added Protease Inhibitor-Realistic SVR rate A. Sheth, T.S. Chiang, S.M. Smith, R.H. Eng Welcome and Remarks 6. Value of Emergency Room Blood Cultures in an Urban VA Medical Center C. Koper, S.M. Smith, R. Kothari, R.H.K. Eng Marc Klapholz, MD Chairman of Medicine 7. Plasmid Transferability of KPC into Virulent K2 Serotype Klebsiella pneumoniae Catherine Koper, Kris Siu, Robert Eng, Tom Chiang Introduction 8. Pituitary Tumor Excision and Associated Perioperative Cardiovascular Complications: A Study of the Nancy Connell, PhD Nationwide Inpatient Sample Director of Research, Department of Medicine Raymond Malapero MD MPH, Sergey Pisklakov MD, Alex Bekker MD 9. A Case of Thyroid Cancer Where it is Least Expected Presentations Shuchie Jaggi DO, Nisha Suda MD, Maya Raghuwanshi MD 10. Resistant Nocardia abscessus Pleural Infection in a Patient with AIDS George R. Nahas, DO Mustache 1 stabilizes TAC1 transcript in breast cancer cells Rahim Wooley, MD, Rajendra Kapila, MD, and Andrew Berman, MD to increase the production of onco-substance P 11. Anaplasmosis in a Deer Hunter Joseph DeRose, D.O. Yucai Wang, MD, PhD Adding VEGFR-TKIs to Chemotherapy and/or Hormonal Therapy in 12.
    [Show full text]
  • 2017 Hematologic Oncology Annual Report
    HEMATOLOGIC ONCOLOGY 2017 ANNUAL REPORT CONTENTS 2 Division of Hematologic Oncology Faculty 4 Letter from the Division Head 5 FDA Approves CAR T Cell Therapy for Non-Hodgkin Lymphoma 6 #AACR17: Study Explores Best Time to Give CAR T Cell Therapy 8 Over 50-Year Career, Dr. Carol Portlock Bears Witness to Evolution of Lymphoma Treatments 10 Study Suggests Ways to Make Bone Marrow Transplants Safer for People with Blood Cancer 12 FDA Approves Enasidenib (IDHIFA), A First-of-its-kind Drug, For Advanced Blood Cancer 14 Eric Smith's Mission: To Add Multiple Myeloma to Approved Uses for Revolutionary CAR T Cell Therapy 15 Nursing Career All in the Family for Nurse Practitioner Coordinator, Nicole LeStrange 16 Elaina Preston, MPH, MSHS, PA-C 17 Adult BMT Research Dietitian, Marissa Buchan, Helps Usher Nutrition Into Forefront of Cancer Care 18 Myeloma Precursor Disease Can Start Much Earlier than Expected, Especially in African Americans 20 Peter J. Solomon 22 2017 Division of Hematologic Oncology Metrics 23 Regional Network 24 Power of Data Drives Hematology Research Project Coordinator Yimei Miao's Efforts to Help Patients 25 2017 American Society of Hematology (ASH) Meeting 26 Clinical Training and Education 27 The Mortimer J. Lacher Lecture & Fellows Conference 28 2017 Nursing and Physician Assistant Accomplishments 29 2017 Pharmacy Accomplishments 31 Survivors / Thrivers 32 Tim's Story 34 The David H. Koch Center for Cancer Care — "Topping-Off" Ceremony 34 MSK Center for Hematologic Malignancies 35 Parker Institute for Cancer Immunotherapy
    [Show full text]
  • Developmental Therapeutics Immunotherapy
    DEVELOPMENTAL THERAPEUTICS—IMMUNOTHERAPY 2500 Oral Abstract Session Clinical activity of systemic VSV-IFNb-NIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma. Joselle Cook, Kah Whye Peng, Susan Michelle Geyer, Brenda F. Ginos, Amylou C. Dueck, Nandakumar Packiriswamy, Lianwen Zhang, Beth Brunton, Baskar Balakrishnan, Thomas E. Witzig, Stephen M Broski, Mrinal Patnaik, Francis Buadi, Angela Dispenzieri, Morie A. Gertz, Leif P. Bergsagel, S. Vincent Rajkumar, Shaji Kumar, Stephen J. Russell, Martha Lacy; Mayo Clinic, Rochester, MN; The Ohio State University, Columbus, OH; Mayo Clinic, Scottsdale, AZ; Division of Hematology, Mayo Clinic, Roches- ter, MN; Vyriad and Mayo Clinic, Rochester, MN Background: Oncolytic virotherapy is a novel immunomodulatory therapeutic approach for relapsed re- fractory hematologic malignancies. The Indiana strain of Vesicular Stomatitis Virus was engineered to encode interferon beta (IFNb) and sodium iodine symporter (NIS) to produce VSV-IFNb-NIS. Virally en- coded IFNb serves as an index of viral proliferation and enhances host anti-tumor immunity. NIS was in- serted to noninvasively assess viral biodistribution using SPECT/PET imaging. We present the results of the phase 1 clinical trial NCT03017820 of systemic administration of VSV-IFNb-NIS among patients (pts) with relapsed refractory Multiple Myeloma (MM), T cell Lymphoma (TCL) and Acute myeloid Leu- 9 kemia (AML). Methods: VSV-IFNb-NIS was administered at 5x10 TCID50 (50% tissue culture infec- 11 tious dose) dose level 1 to dose level 4, 1.7x10 TCID50. The primary objective was to determine the maximum tolerated dose of VSV-IFNb-NIS as a single agent. Secondary objectives were determination of safety profile and preliminary efficacy of VSV-IFNb-NIS.
    [Show full text]
  • For Transformation in Cancer Care Mary Caffrey
    ajmc.com | EBOncology PRECISION MEDICINE Moving Toward the “Tipping Point” for Transformation in Cancer Care Mary Caffrey WHEN ASKED TO GIVE his title before being interviewed on camera, same data sets using real-world analytics, and in 6 weeks we got the Andrew Pecora, MD, FACP, CPE, pauses. This might be the toughest same answer.” The results were presented at the San Antonio Breast question of the day, given the many hats the hematologist/oncol- Cancer Symposium in December.5 ogist wears. Pecora is the chief innovation officer and vice pres- This finding shows how all the data being stored can be ident of cancer services at John Theurer Cancer Center, part of unleashed to save time and lives. “The number of valuable ques- Hackensack University Medical Center and an anchor of Regional tions we can answer by clicking keys instead of waiting months or Cancer Care Associates (RCCA), which has more than 30 locations years is going to transform the pace at which we learn and change in New Jersey, Maryland, and Connecticut.1 behavior,” Pecora said. He is a professor of medicine at his alma mater, the University of EBO asked Pecora if payers could use COTA to predict how much Medicine and Dentistry of New Jersey. He is also the founder and they would save on a given therapy annually if they adopted CNA PECORA executive chairman of COTA, a company created in 2011 to develop use across a health system for patients with certain types of cancer. Andrew Pecora, MD, FACP, CPE, is the chief innovation technology that Pecora said is poised to transform cancer care “That’s the grand finale,” he said, hinting at a publication to come officer and vice president delivery by helping oncologists and other specialists make deci- later this year.
    [Show full text]
  • Cancer Care at the Crossroads  Ny, March 25, 2016
    2016 CANCER CARE AT THE CROSSROADS NY, MARCH 25, 2016 A One-Day International Summit on Innovation, Clinical Benefit and Cost Meet the Sponsors Program 7:45am – 8:00am Opening remarks Setting the stage for the day Opening remarks MIKE MEYER ROBERT DARNELL President, Meyer Consulting MD, PhD, Founding Director and CEO, New York Genome Center; Professor & Senior Physician, The Rockefeller University; Investigator, Howard Hughes Medical Institute 8:00am – 9:15am Round table 1 Cancer care delivery and cost through the lens of health plans, academic centers, pharma and provider groups and how they perveive each other Round table 1 Round Moderator Speaker Speaker Speaker Speaker CHERYL A. MOORE HAL PAZ MACE ROTHENBERG JEFFREY LEBENGER RICHARD SCHILSKY President and COO, MD, Executive Vice President MD, Chief Medical Officer and Senior Vice MD, Chairman & CEO, Summit Medical Group MD, Chief Medical Officer, American New York Genome Center and Chief Medical Officer, Aetna President, Clinical Development & Summit Health Management Society of Clinical Oncology and Medical Affairs, Pfizer Oncology 2 Copyright© 2016 Meyer Consulting meyerconsultinginc.com 3 Meet the Sponsors Program 7:45am – 8:00am Opening remarks Setting the stage for the day Opening remarks MIKE MEYER ROBERT DARNELL President, Meyer Consulting MD, PhD, Founding Director and CEO, New York Genome Center; Professor & Senior Physician, The Rockefeller University; Investigator, Howard Hughes Medical Institute 8:00am – 9:15am Round table 1 Cancer care delivery and cost through the lens of health plans, academic centers, pharma and provider groups and how they perveive each other Round table 1 Round Moderator Speaker Speaker Speaker Speaker CHERYL A.
    [Show full text]
  • A Community-Based Oncology Medical Home Model
    A Community-Based Oncology Medical Home Model November 2019 About ASCO Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Conquer Cancer, the ASCO Foundation, supports the Society by funding groundbreaking research and education across cancer’s full continuum. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, Instagram, and YouTube. To learn more about ASCO’s work on improving quality and value in oncology care, we refer readers to the following articles: • ASCO Principles for Patient-Centered Healthcare Reform • ASCO Guidance Statement: The Cost of Cancer Care • ASCO Criteria for High-Quality Clinical Pathways in Oncology • ASCO Position Statement on Addressing the Affordability of Cancer Drugs • ASCO Statement: Towards Individualized Care for Patients with Advanced Cancer Copyright © 2019 American Society of Clinical Oncology. All rights reserved. A Message from ASCO’s President Dear Colleague: The cancer care delivery system is facing extreme pressures amid rapidly developing science, rising costs, growing financial burden for patients, payer-imposed utilization management practices, and much more. As the healthcare landscape shifts from a fee-for-service to a value-based reimbursement system, innovative payment models are needed to help practices adapt and thrive in this high-stakes environment.
    [Show full text]
  • Beyond Extraordinary
    539805Ar1.qxd:Layout 1 11/7/08 10:48 AM Page 1 Giving Opportunities Name Gift Atrium Promenade $5 million Beyond The Phlebotomy Treatment Center $5 million Extraordinary 3-Level Parking Garage $5 million Auditorium $5 million Family Education Center $5 million Grand Concourse/Waiting Area $2 million Dining Room (48 seats) $2 million Diagnostic Laboratory Suite $2 million Administration Wing $1 million Resource Library $1 million Conference Suite (18 seats) $1 million Conference Wing (4 rooms) $1 million Retail Pharmacy $1 million Food Preparation Instruction Area $500,000 Chairman’s Office Suite $500,000 Tranquility Room $500,000 Hackensack University Medical Center Foundation 360 Essex Street, Suite 301, Hackensack, NJ 07601-8566 www.humcfoundation.com 539805Ar1.qxd:Layout 1 11/7/08 10:48 AM Page 1 Giving Opportunities Name Gift Atrium Promenade $5 million Beyond The Phlebotomy Treatment Center $5 million Extraordinary 3-Level Parking Garage $5 million Auditorium $5 million Family Education Center $5 million Grand Concourse/Waiting Area $2 million Dining Room (48 seats) $2 million Diagnostic Laboratory Suite $2 million Administration Wing $1 million Resource Library $1 million Conference Suite (18 seats) $1 million Conference Wing (4 rooms) $1 million Retail Pharmacy $1 million Food Preparation Instruction Area $500,000 Chairman’s Office Suite $500,000 Tranquility Room $500,000 Hackensack University Medical Center Foundation 360 Essex Street, Suite 301, Hackensack, NJ 07601-8566 www.humcfoundation.com Atrium Promenade atients will be welcomed to the new John Theurer Cancer Left to right Center via the Atrium Promenade, an airy and inviting space offering easy access to all the services they need.
    [Show full text]
  • Beyond Extraordinary 32 Awards and Achievements
    QL536043A_R7_cvr_v7.qxp 11/7/08 12:56 PM Page 1 Beyond Table of Contents Extraordinary 1 Extraordinary Preamble 18 Letter from the Campaign Leadership 20 Campaign Co-Chairs 21 National Campaign Chair 22 Mission Statement 23 Letter from Dr. Andrew Pecora 24 A Place Beyond Extraordinary 32 Awards and Achievements Beyond Extraordinary Hackensack University Medical Center Foundation Concept and Campaign Symbol copyright HUMCF 2008 360 Essex Street, Suite 301, Hackensack, NJ 07601-8566 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or www.humcfoundation.com transmitted in any form or by any means (electronic, mechanical, photocopying, recording or otherwise), without the prior written permission of the copyright owner. Printed by Tanaseybert, LLC QL536043A_R7_cvr_v7.qxp 11/7/08 12:56 PM Page 1 Beyond Table of Contents Extraordinary 1 Extraordinary Preamble 18 Letter from the Campaign Leadership 20 Campaign Co-Chairs 21 National Campaign Chair 22 Mission Statement 23 Letter from Dr. Andrew Pecora 24 A Place Beyond Extraordinary 32 Awards and Achievements Beyond Extraordinary Hackensack University Medical Center Foundation Concept and Campaign Symbol copyright HUMCF 2008 360 Essex Street, Suite 301, Hackensack, NJ 07601-8566 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or www.humcfoundation.com transmitted in any form or by any means (electronic, mechanical, photocopying, recording or otherwise), without the prior written permission of the copyright owner. Printed by Tanaseybert, LLC Beautiful Complex Unique a Life To save it requires the extraordinary. Extraordinary Care At Hackensack University Medical Center, where science is partnered with compassion, our cancer patients receive the best medical care from the most caring people in medicine.
    [Show full text]
  • Physician-Focused Payment Model Technical Advisory Committee LOI: Environmental Scan & Relevant Literature Hackensack Meridian Health (HMH) and COTA Inc
    Physician-Focused Payment Model Technical Advisory Committee LOI: Environmental Scan & Relevant Literature Hackensack Meridian Health (HMH) and COTA Inc. Letter Dated: 11/15/2016 Letter Received: 11/15/2016 Hackensack Meridian Health (HMH) is a large multi-hospital provider of cancer services that has experience with value based payment models with commercial payers. COTA is a big data precision analytic company with patented technology that enables providers to identify and prevent adverse behavioral care variance. The Physician-Focused Payment Model proposed by HMH and COTA will seek to optimize clinical outcomes while reducing total cost of care through a combination of precision diagnostics and therapeutics leveraging precision analytics. This model would feature an oncology bundled payment model in which care choices are driven by experiences of similar patients drawn from real world data, this process is currently known as Cota Nodal Address (CNA) Guided Care. The CNA Guided Care approach, which draws from retrospective data based on homogenously grouped oncology patients, is currently facilitating a move from fee for service to bundled reimbursement within the HNH network, and the proposed PFPM will capitalize on this experience. This proposed model would utilize a bundled pricing model for Medicare cancer patients at HMH. The bundled payment will encompass all payments for an oncology episode, including medical, radiation and surgical oncology associated fees with the episode. HMH will use the COTA's patented CNA system to analyze all attributes specific to a patient and their disease that affect clinical outcomes and cost of care. This system (developed by expert clinicians and based on peer-reviewed literature) organizes data about the cancer patients into homogenous groups to enable big data analytic approaches.
    [Show full text]
  • Getting Oncolytic Virus Therapies Off the Ground
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector MEETING REVIEW Getting oncolytic virus therapies off the ground John C. Bell,* Brian Lichty, and David Stojdl Ottawa Regional Cancer Centre, 503 Smyth Road, Ottawa, Ontario K1H 1C4, Canada *Correspondence: [email protected] An international meeting was held on the development and application of replicating viruses for cancer therapy this past March in Banff, Alberta. In this review, using the presentations at this meeting as a backdrop, we discuss how recent scientif- ic and clinical findings are reshaping the development of oncolytic virus therapeutics. Here we identify some of the obstacles that these therapeutics face and discuss evolving strategies, both preclinically and clinically, that are facilitating oncolytic virus development. Oncolytic viruses are therapeutics that have either been natu- (University of California at San Francisco) pointed out that the rally selected or engineered to specifically grow in and kill tumor defect of L4 mRNA transport from the nucleus of Onyx 015 cells. In general, oncolytic viruses derive their specificity by infected cells can be complemented by heat shock. Indeed, it exploiting cell surface or intracellular aberrations in gene has been shown previously that E1B deleted adenoviruses are expression that arise in malignancies during tumor evolution. As cold-sensitive and replicate as well as wild-type adenovirus at David Kirn (Oxford University Medical School, UK) pointed out, 39°C (Goodrum and Ornelles, 1998). This provides an interest- while conventional chemotherapeutics are currently the best ing new wrinkle to the therapeutic application of Onyx 015, as frontline treatments available, they are limited in their utility by transient temperature spikes in patients may facilitate virus relatively narrow therapeutic windows that rapidly close as growth and killing of tumor cells.
    [Show full text]
  • Fibroblast Growth Factor-2 (FGF2) and Syndecan-1 (SDC1) Are Potential Biomarkers for Putative Circulating CD15+/CD30+ Cells in Poor Outcome Hodgkin Lymphoma Patients
    Thomas Jefferson University Jefferson Digital Commons College of Pharmacy Faculty Papers Jefferson College of Pharmacy 1-1-2013 Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients. Rajendra Gharbaran Hackensack University Medical Center, D. Jurist Research Building, 40 Prospect Avenue, Hackensack, NJ Andre Goy Hackensack University Medical Center, D. Jurist Research Building, 40 Prospect Avenue, Hackensack, NJ Takemi Tanaka Thomas Jefferson University FJongwhanollow this and Park additional works at: https://jdc.jefferson.edu/pharmacyfp Hackensack University Medical Center, D. Jurist Research Building, 40 Prospect Avenue, Hackensack, NJ Part of the Pharmacy and Pharmaceutical Sciences Commons LetChris Kimus know how access to this document benefits ouy Hackensack University Medical Center, D. Jurist Research Building, 40 Prospect Avenue, Hackensack, NJ Recommended Citation GharbarSee next an,page Rajendr for additionala; Goy, authorsAndre; Tanaka, Takemi; Park, Jongwhan; Kim, Chris; Hasan, Nafis; Vemulapalli, Swathi; Sarojini, Sreeja; Tuluc, Madalina; Nalley, Kip; Bhattacharyya, Pritish; Pecora, Andrew; and Suh, K Stephen, "Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients." (2013). College of Pharmacy Faculty Papers. Paper 20. https://jdc.jefferson.edu/pharmacyfp/20 This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools.
    [Show full text]